HOFSETH BIOCARE ASA: årsregnskap 2025 vs 2024
Grew 97215% on revenue, weaker earnings
approved 2026-03-27; registry 2026-07-30; journal 2026 622623
Summary
What changed
Comparing Årsregnskap 2025 with 2024 for HOFSETH BIOCARE ASA. Revenue 267.0k NOK → 259.86m NOK (+97215.2%). Net result -97.90m NOK → -127.58m NOK. Equity 120.42m NOK → -6.32m NOK.
On the constructive side: revenue rose; cash rose; current ratio back above 1×. Pressures included: operating result weakened; net result weakened; equity eroded.
Also worth watching: thin equity buffer; paid-in equity reduced; payroll increased. All figures are taken from the published annual accounts for HOFSETH BIOCARE ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 267.0k NOK to 259.86m NOK (+97215.2% YoY). Calculated
-
↑
Cash rose
Bank deposits 23.23m NOK → 28.64m NOK (+23.3% YoY). Calculated
-
↑
Current ratio back above 1×
Current ratio 0.00× → 525.17×. Calculated
What deteriorated
-
↓
Operating result weakened
Operating result -88.43m NOK → -102.67m NOK (op. margin -33115.5% → -39.5%). Calculated
-
↓
Net result weakened
Net result -97.90m NOK → -127.58m NOK (net margin -36662.3% → -49.1%). Calculated
-
↓
Equity eroded
Book equity 120.42m NOK → -6.32m NOK (equity ratio 31.9% → -1426.0%). Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is -1426.0% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation
-
·
Paid-in equity reduced
Paid-in equity fell 120.42m NOK → 4.11m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Payroll increased
Salary cost 60.30m NOK → 71.10m NOK (22584% → 27% of revenue). Calculated
-
·
Book investments changed
Investment / intangible book value 59.56m NOK → 171.11m NOK. Reported fact